4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round
News & Library
03/03/2021
Walter Global Asset Management, in partnership with Bonnefield Financial’s management team, acquires Canadian farmland asset management leader.
01/25/2021
4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery.
12/18/2020
Appointment of Professor Akiko Iwasaki to Scientific Advisory Board.
10/21/2020
4BIO Capital announces its investment in SparingVision, a genomic medicine company focused on ocular diseases.
07/15/2020
4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board
07/01/2020
4BIO Capital appoints Brian P. McVeigh, a seasoned pharma and biotech industry veteran, as Venture Partner to strengthen 4BIO Capital’s US operations.
06/08/2020
4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin. 8 June 2020
05/20/2020
4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million 20 May 2020
04/30/2020
Discussion on background, progress, and impact of Covid19.
04/30/2020
Media Coverage of the Ventures II Launch
04/30/2020
4BIO Capital raises $50 million in first close of new advanced therapies fund. 4BIO Ventures II fund solely focused on advanced therapies.
03/25/2020
Redpin Therapeutics secures initial closing of $15.5 million in Series A financing. 4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors.